INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA
Institute
South London and Maudsley NHS Foundation Trust
Londres, Reino UnidoPublications in collaboration with researchers from South London and Maudsley NHS Foundation Trust (18)
2023
-
Cognitive Remediation Works But How Should We Provide It? An Adaptive Randomized Controlled Trial of Delivery Methods Using a Patient Nominated Recovery Outcome in First-Episode Participants
Schizophrenia bulletin, Vol. 49, Núm. 3, pp. 614-625
-
Hippocampal Glutamate, Resting Perfusion and the Effects of Cannabidiol in Psychosis Risk
Schizophrenia Bulletin Open, Vol. 4, Núm. 1
-
Increased hippocampal blood flow in people at clinical high risk for psychosis and effects of cannabidiol
Psychological Medicine
-
Satisfaction with cognitive remediation therapy: its effects on implementation and outcomes using the cognitive remediation satisfaction scale
Schizophrenia, Vol. 9, Núm. 1
2022
-
Altered relationship between cortisol response to social stress and mediotemporal function during fear processing in people at clinical high risk for psychosis: a preliminary report
European Archives of Psychiatry and Clinical Neuroscience, Vol. 272, Núm. 3, pp. 461-475
-
The Relationship Between Grey Matter Volume and Clinical and Functional Outcomes in People at Clinical High Risk for Psychosis
Schizophrenia Bulletin Open, Vol. 3, Núm. 1
2021
-
1q21.1 distal copy number variants are associated with cerebral and cognitive alterations in humans
Translational psychiatry, Vol. 11, Núm. 1, pp. 182
-
Adverse clinical outcomes in people at clinical high-risk for psychosis related to altered interactions between hippocampal activity and glutamatergic function
Translational Psychiatry, Vol. 11, Núm. 1
-
Correction: Adverse clinical outcomes in people at clinical high-risk for psychosis related to altered interactions between hippocampal activity and glutamatergic function (Translational Psychiatry, (2021), 11, 1, (579), 10.1038/s41398-021-01705-z)
Translational Psychiatry
-
Integrated metastate functional connectivity networks predict change in symptom severity in clinical high risk for psychosis
Human Brain Mapping, Vol. 42, Núm. 2, pp. 439-451
-
Interactions between hippocampal activity and striatal dopamine in people at clinical high risk for psychosis: relationship to adverse outcomes
Neuropsychopharmacology, Vol. 46, Núm. 8, pp. 1468-1474
2020
-
A single dose of cannabidiol modulates medial temporal and striatal function during fear processing in people at clinical high risk for psychosis
Translational Psychiatry, Vol. 10, Núm. 1
-
Dose response of the 16p11.2 distal copy number variant on intracranial volume and basal ganglia
Molecular Psychiatry, Vol. 25, Núm. 3, pp. 584-602
-
Glutamatergic and dopaminergic function and the relationship to outcome in people at clinical high risk of psychosis: a multi-modal PET-magnetic resonance brain imaging study
Neuropsychopharmacology, Vol. 45, Núm. 4, pp. 641-648
2018
-
Cognitive remediation therapy for psychotic major depressive disorder
Primary Care Companion to the Journal of Clinical Psychiatry
-
The CIRCuiTS study (Implementation of cognitive remediation in early intervention services): Protocol for a randomised controlled trial
Trials, Vol. 19, Núm. 1
2016
-
Heterogeneity of psychosis risk within individuals at clinical high risk: A meta-analytical stratification
JAMA Psychiatry, Vol. 73, Núm. 2, pp. 113-120
-
Neurobiological models of self-disorders in early schizophrenia
Schizophrenia Bulletin, Vol. 42, Núm. 4, pp. 874-880